Search results
EAN 2024: Benefits of early migraine treatment clear but implementation remains challenging
Clinical Trials Arena· 12 hours agoA further key challenge highlighted during the symposium is that due to the variability of migraine...
10 clinical trials to watch in the second half of 2024
BioPharma Dive· 3 days agoStudy results are expected for two closely watched obesity drugs, while key tests await for a...
FDA Approves Skyrizi for Ulcerative Colitis
Verywell Health· 5 days agoThe FDA approves Skyrizi for the treatment of Ulcerative colitis. Here's what approval means and how the drug compares to other treatment options...
Coherus offloads Humira biosimilar Yusimry for $40m
Pharmaceutical Technology· 5 days agoCoherus Biosciences has divested Yusimry (adalimumab-aqvh), a biosimilar to AbbVie’s rheumatoid arthritis therapy Humira, to Hong Kong King-Friend...
Rocket gene therapy rejected by FDA over manufacturing
BioPharma Dive· 6 days agoBiotechnology companies aren’t the only ones running into issues. Both Daiichi Sankyo and AbbVie...
AbbVie completes acquisition of Celsius Therapeutics for $250m
Pharmaceutical Technology· 6 days agoAbbVie has acquired biotechnology company Celsius Therapeutics in a deal valued at $250m in cash....
Nexalin’s deep brain stimulation add-on therapy alleviates depression
Medical Device Network· 7 days agoThe company’s deep brain stimulation device used in combination with medication is more effective in...
AbbVie expands its IBD prospects with $250M Celsius deal
BioPharma Dive· 7 days agoHunting another immunology drug, AbbVie announced Thursday it’s paying $250 million to acquire...
AbbVie gains FDA approval for EPKINLY in follicular lymphoma
Pharmaceutical Technology· 7 days agoAbbVie has announced accelerated approval from the US Food and Drug Administration (FDA) for EPKINLY...